A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Upadacitinib (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-EARLY
- Sponsors AbbVie
- 06 Oct 2017 Planned End Date changed from 9 Aug 2020 to 28 Mar 2021.
- 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Aug 2017 Planned End Date changed from 27 Mar 2021 to 9 Aug 2020.